These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 18759214)
41. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Chan WM; Lai TY; Liu DT; Lam DS Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318 [TBL] [Abstract][Full Text] [Related]
42. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Finger RP; Charbel Issa P; Ladewig M; Holz FG; Scholl HP Br J Ophthalmol; 2008 Apr; 92(4):483-7. PubMed ID: 18369065 [TBL] [Abstract][Full Text] [Related]
43. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Chan WM; Lai TY; Liu DT; Lam DS Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414 [TBL] [Abstract][Full Text] [Related]
44. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib]. Maier M; Feucht N; Huebner M; Lohmann C Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780 [TBL] [Abstract][Full Text] [Related]
45. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Modarres M; Naseripour M; Falavarjani KG; Nikeghbali A; Hashemi M; Parvaresh MM Retina; 2009 Mar; 29(3):319-24. PubMed ID: 19287288 [TBL] [Abstract][Full Text] [Related]
46. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Arias L; Caminal JM; Casas L; Masuet C; Badia MB; Rubio M; Pujol O; Arruga J Br J Ophthalmol; 2008 Dec; 92(12):1636-41. PubMed ID: 18782803 [TBL] [Abstract][Full Text] [Related]